Globus Medical wins patent infringement case against Life Spine, securing damages for its expandable spinal fusion implant technology.
Quiver AI Summary
Globus Medical, Inc. announced that a Delaware jury ruled in its favor in a patent infringement case against Life Spine, Inc., determining that Life Spine’s Prolift implants infringed on several claims of Globus’s patent and awarding damages for lost profits and reasonable royalties. The case involved expandable spinal fusion implants, which are significant for improving surgical outcomes. Globus's CEO, Keith Pfeil, expressed satisfaction with the verdict, emphasizing the company’s commitment to innovation in musculoskeletal technology. Additionally, Globus has similar ongoing litigation against Alphatec, Inc. regarding expandable implant technology. The company reaffirmed its dedication to protecting its intellectual property and investing in patient-related innovations.
Potential Positives
- Globus Medical won a significant patent infringement case against Life Spine, reinforcing their intellectual property rights and protecting their technology in expandable spinal fusion implants.
- The jury awarded Globus damages, including lost profits and reasonable royalties, indicating a strong financial outcome from the litigation.
- The decision highlights Globus's position as a leader in musculoskeletal innovation, potentially enhancing their reputation in the medical community.
- The company expressed its commitment to continue enforcing its patent rights and investing in research and development, emphasizing ongoing innovation that benefits patients worldwide.
Potential Negatives
- The ongoing litigation against Alphatec, Inc. suggests that Globus may face continued legal challenges related to its intellectual property, which could lead to additional costs or distractions from core business activities.
- The inclusion of a long list of potential risks and uncertainties in the forward-looking statements could create concerns for investors regarding the company's future performance and ability to navigate these challenges.
- The need to enforce patent rights against competitors indicates that there may be significant competition in the market for expandable spinal implants, which could impact Globus's market share and profitability.
FAQ
What was the outcome of the patent trial involving Globus Medical?
A Delaware jury found in favor of Globus Medical in its patent infringement case against Life Spine, Inc.
What technology was at the center of the patent infringement case?
The case involved expandable spinal fusion implants, an advancement in surgical patient care.
What damages were awarded to Globus Medical?
The jury awarded Globus both lost profits and reasonable royalty damages in the verdict.
What statement did Globus's CEO make regarding the verdict?
CEO Keith Pfeil affirmed the strength of Globus's intellectual property and innovation in expandable implant technologies.
Is Globus Medical involved in any other patent litigation cases?
Yes, Globus has pending litigation against Alphatec, Inc. regarding expandable implant and retractor technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GMED Congressional Stock Trading
Members of Congress have traded $GMED stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $GMED stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 06/17 and 2 sales worth up to $30,000 on 07/10, 06/24.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 04/09.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$GMED Insider Trading Activity
$GMED insiders have traded $GMED stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $GMED stock by insiders over the last 6 months:
- ANN D RHOADS sold 7,500 shares for an estimated $590,100
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GMED Hedge Fund Activity
We have seen 258 institutional investors add shares of $GMED stock to their portfolio, and 298 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MADISON AVENUE PARTNERS, LP added 1,712,148 shares (+inf%) to their portfolio in Q2 2025, for an estimated $101,050,974
- JANUS HENDERSON GROUP PLC added 1,200,676 shares (+17.1%) to their portfolio in Q2 2025, for an estimated $70,863,897
- RTW INVESTMENTS, LP removed 1,125,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $66,397,500
- INVESCO LTD. removed 1,099,608 shares (-54.4%) from their portfolio in Q2 2025, for an estimated $64,898,864
- FULLER & THALER ASSET MANAGEMENT, INC. removed 919,115 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $54,246,167
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 873,784 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $51,570,731
- MARSHALL WACE, LLP added 747,330 shares (+89.7%) to their portfolio in Q2 2025, for an estimated $44,107,416
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GMED Analyst Ratings
Wall Street analysts have issued reports on $GMED in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 08/08/2025
- Morgan Stanley issued a "Overweight" rating on 07/15/2025
- Piper Sandler issued a "Overweight" rating on 05/09/2025
To track analyst ratings and price targets for $GMED, check out Quiver Quantitative's $GMED forecast page.
$GMED Price Targets
Multiple analysts have issued price targets for $GMED recently. We have seen 5 analysts offer price targets for $GMED in the last 6 months, with a median target of $68.0.
Here are some recent targets:
- Vik Chopra from Wells Fargo set a target price of $66.0 on 08/08/2025
- William Plovanic from Canaccord Genuity set a target price of $90.0 on 07/22/2025
- Drew Ranieri from Morgan Stanley set a target price of $68.0 on 07/15/2025
- Richard Newitter from Truist Securities set a target price of $68.0 on 05/12/2025
- Matt O'Brien from Piper Sandler set a target price of $80.0 on 05/09/2025
Full Release
AUDUBON, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globus in its patent infringement litigation against Life Spine, Inc.
The jury found that Life Spine’s Prolift family of implants infringed several claims of a valid Globus patent and awarded Globus both lost profits and reasonable royalty damages. The technology at issue involves expandable spinal fusion implants, an important advancement in patient care that can help improve outcomes in spinal surgery.
“We are pleased with the jury’s decision, which affirms the strength of our intellectual property and the groundbreaking innovation behind our expandable implant technologies,” said Keith Pfeil, President and Chief Executive Officer. “This verdict underscores Globus’s place as a leading innovator in the musculoskeletal field.”
In addition to the Life Spine case, Globus has a separate patent infringement litigation pending against Alphatec, Inc. involving expandable implant and retractor technology. The company stated that it remains committed to protecting its intellectual property while continuing to focus on innovation that benefits patients worldwide.
“We invest in research and development to bring transformative solutions to patients worldwide,” added Kelly Huller, Executive Vice President and General Counsel. “We will not hesitate to enforce our patent rights against those who attempt to use our technology without authorization.”
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at
www.globusmedical.com
.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive and Nevro businesses and our ability to successfully integrate and achieve anticipated synergies with the integration, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosure of Globus Medical contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at
www.sec.gov
. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Investor contact:
Brian Kearns
SVP, Corporate Development and Investor Relations
610-930-1800
[email protected]
Media contact:
Moran Chavez
[email protected]